GeoVax Labs, Inc. has released its year-end financial results and highlighted key achievements, including ongoing preparations for a Phase 2b trial of GEO-CM04S1 and upcoming clinical evaluations of GEO-MVA and Gedeptin(R). The company will discuss these updates and financial results in a conference call.